Authors: Giuseppe Esposito, Marcella Pesce, Luisa Seguella, Walter Sanseverino, Jie Lu, Chiara Corpetti, Giovanni Sarnelli
Institutions:
Publication: British Journal of Pharmacology
Date: July 2020
Full paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300643/
Abstract:
Identifying drugs effective in the new coronavirus disease 2019 (COVID‐19) is crucial, pending a vaccine against SARS‐CoV2. We suggest the hypothesis that cannabidiol (CBD), a non‐psychotropic phytocannabinoid, has the potential to limit the severity and progression of the disease for several reasons:‐ (a) High‐cannabidiol Cannabis sativa extracts are able to down‐regulate the expression of the two key receptors for SARS‐CoV2 in several models of human epithelia, (b) cannabidiol exerts a wide range of immunomodulatory and anti‐inflammatory effects and it can mitigate the uncontrolled cytokine production responsible for acute lung injury, (c) being a PPARγ agonist, it can display a direct antiviral activity and (d) PPARγ agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients. We hope our hypothesis, corroborated by preclinical evidence, will inspire further targeted studies to test cannabidiol as a support drug against the COVID‐19 pandemic.
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del si...
La revista ‘Nature Protocols’ selecciona esta técnica como “pro...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory